CyMedica Orthopedics announces the launch of a clinical trial to evaluate the effectiveness of its e-vive muscle strengthening device and patient engagement system in knee osteoarthritis (OA) patients.
In the study, researchers will combine muscle-strengthening data from the e-vive device with activity and health data collected by wearable smartwatch devices to determine how well the e-vive improves OA symptoms.
The randomized, prospective clinical trial, led by Matthew Stewart Hepinstall, MD (Primary Investigator) and Michael A. Mont, MD, will be conducted on 120 osteoarthritis patients in clinical collaboration with Northwell Health, according to a media release from CyMedica Orthopedics.
“The e-vive clinical trial for knee osteoarthritis marks a major advancement for CyMedica in the treatment landscape for managing osteoarthritis knee pain,” says Rob Morocco, its president and chief executive officer.
“It comes at a time when an overwhelming number of knee arthritis patients are in urgent need of non-narcotic, non-addictive and home-based wearable therapies to help the millions of Americans who suffer from this painful chronic condition.”
Muscle weakness is considered one of the most common underlying clinical conditions associated with knee osteoarthritis and the rehabilitation challenges facing patients recovering from knee procedures.
“Through this clinical trial, CyMedica and Northwell Health have a unique opportunity to positively measure the effectiveness of e-vive muscle strengthening using a novel, app-based patient-engagement system and smartwatch technology, which patients are already wearing,” states Dr Michael A. Mont, vice president of strategic operations in orthopedics at Northwell Health.
“In turn, patients are able to better manage their symptoms earlier in their knee osteoarthritis journey,” he adds.
[Source(s): CyMedica Orthopedics, PR Newswire]
